Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 26 to 50 of 295

Type: GuidanceRemove Type: Guidance filter

Guidance and quality standards awaiting development
Title	Type
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]	Technology appraisal guidance
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor ID 6476	Technology appraisal guidance
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer ID6481	Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769	Technology appraisal guidance
Benralizumab for previously treated severe nasal polyps [ID1659]	Technology appraisal guidance
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]	Technology appraisal guidance
Bentracimab for reversing the antiplatelet activity of ticagrelor TS ID 10550	Technology appraisal guidance
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]	Technology appraisal guidance
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years TSID 12054	Technology appraisal guidance
BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]	Technology appraisal guidance
Bimekizumab for treating ankylosing spondylitis TS ID 10334	Technology appraisal guidance
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991	Technology appraisal guidance
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592	Technology appraisal guidance
Botulinum toxin type A for preventing episodic migraine ID 6450	Technology appraisal guidance
Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over ID 6448	Technology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]	Technology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma ID 6437	Technology appraisal guidance
Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over ID6486	Technology appraisal guidance
Bupivacaine–meloxicam for treating postoperative pain [ID2728]	Technology appraisal guidance
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]	Technology appraisal guidance
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]	Technology appraisal guidance
CAEL-101 with standard care for untreated amyloid light chain amyloidosis TS ID 10666	Technology appraisal guidance
Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888	Technology appraisal guidance
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency ID 6466	Technology appraisal guidance
Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy TS ID 10214	Technology appraisal guidance

Results per page

10
25
50
All